Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Man Group plc cut its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 23.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,059 shares of the company’s stock after selling 30,803 shares during the period. Man Group plc owned approximately 0.15% of Amylyx Pharmaceuticals worth $378,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. raised its stake in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after buying an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. Alpine Global Management LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. RPO LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $46,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $53,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 12,425 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $43,114.75. Following the sale, the insider now owns 194,375 shares in the company, valued at $674,481.25. This trade represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $37,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 44,811 shares of company stock worth $155,494. 11.70% of the stock is owned by insiders.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $5.31 on Tuesday. The stock’s 50 day simple moving average is $4.34 and its 200 day simple moving average is $4.16. The stock has a market cap of $473.34 million, a P/E ratio of -1.39 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AMLX shares. Leerink Partners raised Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. Mizuho increased their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 14th. HC Wainwright increased their target price on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Finally, Leerink Partnrs upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.83.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.